SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing a massive surge fueled by sympathy momentum from Intel's strong earnings report and bullish analyst upgrades that highlight rising CPU demand in AI data centers. While the community remains deeply polarized between long-term bulls targeting higher valuations and skeptics warning of an overextended bubble, traders are actively debating the sustainability of this rapid upward move.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant market momentum driven by a strong earnings beat and positive forward guidance, fueling widespread discussion about a potential CPU renaissance in AI-driven data centers. While the community is actively debating the sustainability of this rapid re-rating and debating whether to take profits or hold for long-term growth, analysts are rapidly revising their price targets in response to the surge.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The community is actively debating the sustainability of the semiconductor sector's parabolic rally, with many traders using $SOXS as a tactical hedge against perceived overextension and AI-driven euphoria. Amidst heavy volume, market participants are split between those betting on a major blow-off top and others warning that the instruments structural decay makes it a dangerous hold during sustained periods of upward sector momentum.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz is trending following a significant jury verdict awarding the company hundreds of millions in damages against rival Papaya Gaming for the use of bots. While the community is actively debating the stock's potential for a massive squeeze or further volatility, investors remain focused on the potential for additional disgorgement rulings and the company's improved financial outlook.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing intense investor activity driven by a parabolic rally in the semiconductor sector, fueled by massive AI-driven infrastructure demand and consistent momentum that has kept the ETF trending higher. While many in the community are celebrating record gains and speculative targets, others are actively debating whether this represents a sustainable super-cycle or a dangerous bubble approaching a blow-off top.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is surging due to positive financial results and guidance that emphasize a strategic pivot into AI-driven data center infrastructure. The community is actively debating the sustainability of this sharp rally, with many traders discussing the potential for a continued momentum trade versus concerns that the stock may be overextended.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant attention as investors weigh the potential of its oral Wegovy pill against Eli Lilly's recent market entry, with the company's new AI partnership with OpenAI further fueling hopes for accelerated drug discovery. Despite recent share price volatility, the community is actively debating the stock's valuation, dividend yield, and the long-term impact of evolving GLP-1 competitive dynamics.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense buying activity and high volume as investors react to confirmed purchase orders linked to Marvell Technologies and ongoing speculation about partnerships with major cloud hyperscalers. Community sentiment is overwhelmingly bullish, with many traders framing the recent price action as a structural breakout that is forcing short sellers to cover their positions.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as retail and institutional investors debate whether the sector is experiencing a historic AI-driven bull run or a dangerous bubble fueled by speculative circular financing. While many community members highlight the ETF's aggressive momentum and its role as a market leader, skeptics are expressing concern over overvaluation, supply chain bottlenecks, and increasing data center project delays.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is rallying strongly following the company's strategic unveiling of its first AGI CPU, which marks a significant shift into in-house silicon design for data centers and heightened competition with major industry players. Investors are actively discussing the stock's transition from an IP licensor to a direct hardware competitor, while community sentiment remains split between excitement over the potential for massive AI-driven valuation expansion and concerns regarding the sustainability of the stock's high trading multiples.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

uniQure (NASDAQ:QURE) Shares Up 9.1% - Still a Buy?

uniQure (NASDAQ:QURE) Trading 9.1% Higher - Should You Buy...

uniQure N.V. (NASDAQ:QURE) Sees Significant Decrease in Short Interest

uniQure N.V. (NASDAQ:QURE - Get Free Report) was the target of a large decline in short interest in March. As of March 31st, there was short interest totaling 10,981,448 shares, a decline of 13.7...

uniQure (NASDAQ:QURE) Trading Down 3.7%  - Here's What Happened

uniQure (NASDAQ:QURE) Trading Down 3.7% - Time to Sell...

<ul class="summary-bullets"><li>Hemmati served as Capricor’s vice president of medical and clinical development for new therapies between 2015 and 2017.</li><li>Capricor is awaiting an FDA decision on its DMD therapy, Deramiocel, expected by Aug. 22.</li><li>The FDA resumed review last month after issuing a Complete Response Letter in July 2025, requesting additional clinical data.</li></ul>Shares of Capricor Therapeutics (CAPR) jumped 1% in premarket trading on Tuesday after reports said a former company executive is being considered to lead the FDA’s top gene therapy division just months before a key approval decision on its Duchenne muscular dystrophy (DMD) treatment.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> jumped 11% on Monday to end at $34.54, logging its best session in nearly two months.<h2 class="st-heading-2">Former Capricor Executive Emerges As FDA Biologics Chief Candidate</h2>Houman Hemmati, who served as vice president of medical and clinical development for new therapies at Capricor between 2015 and 2017, is among the candidates being interviewed by FDA Commissioner Marty Makary to head the Center for Biologics Evaluation and Research, or CBER, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-13/eye-doctor-considered-for-fda-vaccine-post-is-a-fox-news-regular">reported</a>.The division oversees approvals of vaccines and advanced gene and cell therapies, including treatments for rare diseases such as DMD. However, HHS spokesperson Andrew Nixon reportedly said no selection has been finalized and that the agency is still evaluating candidates.<h2 class="st-heading-2">CAPR Awaits Key FDA Ruling On DMD Therapy</h2>The development comes as Capricor awaits an FDA decision on Deramiocel, its investigational therapy for DMD, a rare genetic condition that causes progressive muscle weakness in children, expected by Aug. 22.The FDA resumed review of Deramiocel last month after issuing a Complete Response Letter (CRL) in July 2025, which indicated earlier that the agency could not approve the drug in its current form and typically requests additional data. Capricor’s resubmission included Phase 3 Hope-3 trial results showing 54% slower deterioration in upper-limb function and 91% slowing of cardiac disease progression, both statistically significant compared with placebo.Deramiocel consists of donor-derived cardiac cells, which reduces inflammation linked to muscle degeneration in DMD.<h2 class="st-heading-2">Prasad Exit Seen As Positive For Biotech Approvals</h2>The CBER leadership opening follows the departure this month of outgoing director Vinay Prasad, whose tenure drew criticism from the biotech industry over regulatory decisions affecting rare-disease therapies.Prasad’s exit news lifted several biotech stocks last month, with BMO Capital Markets calling the change “a sigh of relief” for the sector and saying it could improve approval prospects for multiple companies developing advanced therapies.During his tenure, Prasad was involved in disputes with companies, including Sarepta Therapeutics, over gene-therapy reviews and disagreements with UniQure and Regenxbio. He also briefly stepped away from the agency last year amid political criticism over regulatory decisions before returning weeks later with Makary’s support.<h2 class="st-heading-2">How Do Retail Traders Feel About CAPR?</h2>On Stocktwits, retail sentiment for CAPR jumped to ‘bullish’ from ‘bearish’ levels over the past day amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_26c2d1b5ac.webp" alt="capr ss.png" width="963" height="149"><figcaption>CAPR sentiment and message volume as of April 14 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/graywolf/message/650157552">said</a>, “$45-50 is my guess if the appointment is confirmed. 75+ upon approval, and $100+ with sale numbers,” referring to the prospects of Hemmati leading the CBER.<stembedurl>https://stocktwits.com/graywolf/message/650157552</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/WBinthehouse/message/650152118">said</a>, “if Dr Hemmati gets appointed as CBER chief, Vinay Prasad is gonna want credit for CAPRs approval. Will beat David to the punch. Guaranteed! Lol”<stembedurl>https://stocktwits.com/WBinthehouse/message/650152118</stembedurl>CAPR stock has jumped over 270% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-killers-musk-taunts-rivals-after-q1-us-deliveries-top-ev-market/cZJpx1BRIHE">'What Happened To All The Tesla Killers?' Elon Musk Taunts Rivals As Q1 US Deliveries Beat Every Other EV Maker Combined</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision

Outgoing CBER director Vinay Prasad will depart this month, boosting approval prospects for several rare-disease therapies.

Equity

uniQure (NASDAQ:QURE) Trading Up 10.9% - Still a Buy?

uniQure (NASDAQ:QURE) Stock Price Up 10.9% - Time to Buy...

QURE CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V. (uniQure or the Company) (NASDAQ: QURE) and reminds investors of the April 13...

QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit PR Newswire...

uniQure N.V. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against uniQure N.V. - QURE

Kahn Swick & Foti, LLC (KSF) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 13, 2026to file lead plaintiff applications...

QURE Deadline: Rosen Law Firm Urges uniQure N.V. (NASDAQ: QURE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025...

QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 QURE UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds uniQure (QURE...

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

QURE
uniQure NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QURE News

QUREuniQure NV